Evotec picks Genedata Screener for drug discovery data management

High-throughput screening

Evotec has chosen Genedata Screener to manage data at its high-throughput screening operation. The deal is the latest in a string of agreements unveiled by Genedata in the past 18 months, over which period Bayer, Boehringer Ingelheim and Merck KGaA have all signed up to use its software.

German CRO Evotec will use Genedata Screener at its high-content and high-throughput screening (HCS/HTS) units. Genedata has designed Screener to serve as a single platform for the analysis and storage of data from all types of plate-based screening. Evotec was already using the software to support the cell screening performed at its HCS unit. Now, it has licensed the tool for use at its HTS operation.

The deal is, in part, underpinned by the earlier successes of Screener. Amgen ($AMGN), Chugai Pharmaceutical and, according to Genedata, more than half of leading pharma companies use the software. For Evotec, a CRO that works closely with the drug discovery teams at leading biopharma companies, there is value in using the same data analysis methodology and management platform as its customers.

“Genedata Screener is one of the standard screening platforms for many of our pharmaceutical customers,” Evotec EVP Dirk Ullmann said in a statement. “Standardizing result generation and quality control, Screener is key to our customer collaborations because it allows everyone to quickly understand the results and result quality. It enables our scientists to deliver results quickly and easily to our customers.”

Evotec’s HCS and HTS units have a long-standing relationship with Genedata. In 2005, the companies teamed up to co-market their HCS and HTS capabilities. That deal married an earlier version of Screener to screening instrumentation and analysis software developed by Evotec.

Since then, Basel, Switzerland-based Genedata has continued to work closely with drug discovery organizations in neighboring Germany. Over the past 18 months, Genedata has unveiled two deals with Boehringer and separate agreements with Bayer and Merck KGaA. With the companies signing up to use multiple different pieces of software, the deals have demonstrated the growing breadth of Genedata’s software portfolio.

- read the release

Related Articles:
Evotec evolves as it announces first-ever spinoff and new business model
Boehringer signs up to use Genedata biologics R&D data platform
Bayer pairs Genedata Profiler and iRODS to manage omics data analysis